|Emitents||Grindeks, AS (5299006DWR32NKWM1O86)|
|Veids||3.1. Papildu regulētā informācija, kas ir jāatklāj saskaņā ar dalībvalsts tiesību aktiem|
JSC “Grindeks” announces completion of acquisition of 100% shares of “HBM Pharma” s.r.o. (Slovakia) from “Dashdirect Limited” (Cyprus) as of June 21, 2018. The total contract amount was 18.2 million euro and JSC “Grindeks” has fully paid it under the terms of agreement.
The core business of “HBM Pharma” s.r.o. is manufacturing of pharmaceuticals and JSC “Grindeks” has conducted a long-term agreement with the company on manufacturing of medication in form of injections.
Therefore, the Group of “Grindeks” consists of four subsidiaries – JSC “Tallinn Pharmaceutical Plant” (Estonia), JSC “Kalceks” (Latvia), “Namu apsaimniekošanas projekti” Ltd. (Latvia), and “HBM Pharma” s.r.o. (Slovakia).
“Grindeks” specializes in the heart and cardiovascular, CNS, anti-cancer and gastroenterological medication therapeutic groups. A range of products covers a combination of original products Mildronate® (meldonium*) and Ftorafur®, generics, food supplements and active pharmaceutical ingredients.
In 2017 products of the company were exported to 77 countries with export comprising 92.5% of the total turnover. The key markets include the EU countries, Russia and the other CIS countries, the U.S., Canada, Japan and Vietnam.
To increase production capacity and develop infrastructure, the company has accomplished many significant investment projects, investing around 100 million euros over the last 15 years.
*Notice: meldonium is included in the list of substances prohibited in sport.